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Abstract 
Background: Centrosomal protein 78 (CEP78) has been characterized as a component of the centrosome required 
for the regulation of centrosome-related events during the cell cycle, but its role in human cancers remains unclear. 
This study aimed to investigate the role and the clinical value of CEP78 in colorectal cancer (CRC).
Methods: Quantitative real-time polymerase chain reaction (qRT-PCR) and immunohistochemistry were performed 
to examine CEP78 expression in CRC tissues and adjacent noncancerous tissues. The association between CEP78 
expression and clinical outcomes of CRC patients was determined. The effect of CEP78 on cell growth was examined 
in vitro by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) assay, colony formation, and flow 
cytometry assays and in vivo using a nude mouse model.
Results: The expression level of CEP78 was significantly lower in tumor tissues than in the adjacent normal tissues 
(P < 0.01). Low CEP78 expression was significantly associated with poor differentiation (P = 0.003), large tumor size 
(P = 0.017), lymphatic metastasis (P = 0.034), distant metastasis (P = 0.029), and advanced stage (P = 0.011). Kaplan–
Meier analysis indicated that patients with low CEP78 expression had shorter survival than those with high CEP78 
expression (P < 0.01). Overexpression of CEP78 in CRC cells significantly reduced cell viability and colony formation 
in vitro and halted tumor growth in vivo. Further study showed that CEP78 reintroduction in CRC cells resulted in 
G2/M phase arrest rather than cell apoptosis.
Conclusions: CEP78 might function as a tumor suppressor and serve as a novel prognostic marker in CRC.
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Background
Colorectal cancer (CRC) is the third most prevalent can-
cer worldwide, with over 1.4 million new cancer cases 
diagnosed and 693,900 deaths in 2012 [1]. Additionally, 
the incidence and mortality of CRC are increasing yearly 
in China [2]. The development of CRC is a long and com-
plicated process accompanied by the combined activa-
tion of oncogenes and inactivation of tumor suppressor 
genes [3, 4]. Although an increasing number of molecules 
have been found to be implicated in CRC over the years, 
it is still necessary and urgent to identify genes that are 
crucial for tumor development in specific genetic con-
texts, which could further improve the early detection, 
prevention, intervention, and prognostic evaluation of 
patients with CRC.
The centrosome is a critical cellular organelle that func-
tions as the microtubule-organizing center of cells and is 
critically involved in cell division [3, 5]. Centrosomal pro-
teins (CEPs) are usually defined as the molecules that are 
localized at the centrosome and participate in the regu-
lation of centrosome-related function [6]. For instance, 
CEP76 specifically prevents centriole re-duplication by 
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limiting duplication to one per cell cycle [7]. CEP120 is 
required for centriole duplication, maturation, and sub-
sequent ciliogenesis, which physiologically affects cer-
ebellar and embryonic development [8]. Regarding the 
cell cycle, centrosome duplication is periodically regu-
lated in a highly choreographed manner and is accord-
ingly coupled to activities of cyclin-dependent kinases 
(CDKs). Reciprocally, the activities of CDKs are affected 
by centrosome status. The inhibition or silencing of sev-
eral centrosome-associated proteins, such as dynactin, 
poly(ADP-ribose) polymerase 3 (PARP3), centriolin, and 
A-kinase anchor protein 450 (AKAP450), could block 
cell cycle progression [9]. Because dysregulation of the 
cell cycle commonly occurs during tumor development 
[10], CEPs potentially participate in tumorigenesis under 
certain genetic contexts. Recently, CEP55 was found to 
be overexpressed and positively correlated with tumor 
growth in CRC [11, 12]. However, the functions of CEPs 
in tumor development remain elusive and merit further 
investigation.
The CEP78 gene, located on chromosome 9q21.2, 
encodes a 78-kDa protein CEP78. CEP78 was identified 
as a component of the centrosome through mass spec-
trometry-based proteomic analysis. However, whether 
and how CEP78 is coordinated with centrosome activi-
ties remain unknown [6]. A previous study demonstrated 
that CEP78 might be involved in treatment-associated 
immune responses in patients with prostate cancer [13]. 
However, the clinical implication and functions of CEP78 
relevant to tumorigenesis are largely unknown.
In this study, the expression of CEP78 in CRC was 
determined. Additionally, the relationship between the 
clinicopathologic parameters of CRC patients and CEP78 
was examined. The antitumor effect of CEP78 was inves-
tigated in vitro and in vivo.
Methods
Cell lines and patient tissue samples
Paraffin-embedded primary specimens were obtained 
from 237 CRC patients with complete clinicopathologic 
data. Matched adjacent normal tissues were obtained 
from 158 patients. The patients were diagnosed at 
the Sun Yat-sen University Cancer Center (SYSUCC), 
Guangzhou, China between 1999 and 2007. None of 
the patients had received radiotherapy or chemotherapy 
prior to surgery. The cohort consisted of 127 (53.6%) men 
and 110 (46.4%) women. The clinical stage of CRC was 
evaluated on the basis of the TNM classification system 
[14]. The clinicopathologic characteristics of these CRC 
patients are shown in Table 1. An additional eight paired 
fresh CRC tissues, along with the corresponding non-
tumorous tissues, were collected for RNA extraction. All 
samples were anonymous. Written consent was obtained 
from all patients. The study and consent procedure were 
approved by the Institutional Research Ethics Committee 
of SYSUCC.
CRC cell lines (SW480, SW620, HCT116, HT29, 
DLD1, LOVO, RKO, and THC8307) were obtained from 
the American Type Culture Collection (ATCC) and cul-
tured according to the instructions of ATCC.
Construction of stable cell lines overexpressing CEP78
Full-length human CEP78 cDNA was cloned into a pSin-
puro vector (GenePharma, Shanghai, China), and CEP78 
was verified by DNA sequencing. The primers were 
5′-GGAATTCCATATGACCATGATCGACTCCGTG 
AAGCTG-3′ (forward) and 5′-CTAGCTAGCTCAGGA 
ATGCAGGTCCTTTCC-3′ (reverse). pSin-puro-CEP78 
or the pSin-puro empty vector was co-transfected with 
pMD.2G and psPAX2 into HEK-293T cells for 48 h. The 
recombinant viruses were collected and used to infect 
HT29 and HCT116 cells, which were cultured with 8 μg/mL 
polybrene for 24 h. Stable lines were selected with 1 μg/
mL of puromycin for 2 weeks.
RNA extraction and quantitative real‑time polymerase 
chain reaction (qRT‑PCR)
The total RNA of fresh CRC specimens was isolated 
using Trizol (Invitrogen, Carlsbad, CA, USA) accord-
ing to the manufacturer’s protocol. First-strand cDNA 
was synthesized using PrimeScript® RT reagent kit with 
gDNA Eraser (Fermentas, Burlington, ON, Canada). 
Semi-qRT-PCR and qRT-PCR were performed for the 
detection of CEP78 mRNA using Advantage HD DNA 
Polymerase Mix (Takara, Shimogyo-ku, Kyoto, Japan) 
and SYBR® Premix Ex Taq™ II (Takara), respectively. The 
primer sequences were as follows: 5′-TGGCAGGGAG 
CAGATCACA-3′ (forward) and 5′-AAGCCAGCCATA 
CAGTCAAGA-3′ (reverse) for CEP78; 5′-ACAGTCAGC 
CGCATCTTCTT-3′ (forward) and 5′-GACAAGCTTCC 
CGTTCTCAG-3′ (reverse) for GAPDH. The qRT-PCR 
reaction conditions were as follows: 98 °C for 2 min fol-
lowed by 35 cycles of 98 °C for 10 s, 60 °C for 5 s, 72 °C 
for 30 s, and 72 °C for 10 min, and, finally, hold at 4 °C. 
The products were analyzed by 2% agarose gel electro-
phoresis and stained with ethidium bromide for visuali-
zation using ultraviolet light.
Western blotting
Western blotting was performed as previously described 
[15]. Cell lysates were resolved by sodium dodecyl sul-
fate-polyacrylamide gel electrophoresis (SDS-PAGE) 
and transferred to polyvinylidene fluoride (PVDF) mem-
branes, which were then incubated with anti-CEP78 anti-
body (Sigma, St. Louis, MO, USA) in 5% non-fat milk. 
Then, the membrane was incubated with horseradish 
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peroxidase (HRP)-conjugated anti-rabbit secondary 
antibody. The blots were then visualized using an elec-




lium bromide (MTT) assay was used to measure the cell 
viability as previously described [16]. Cells were seeded 
at a density of 2500 or 3000 per well in 96-well micro-
plates. The cells were incubated with MTT for 4 h, the 
optical density (OD) was detected at 490  nm with a 
microplate reader, and measurements were acquired 
once per day for 5 days. The results are presented as the 
mean  ±  standard error of mean (SEM) of three inde-
pendent experiments.
Colony formation assay
Cells were plated in the 6-well culture plates at 250 cells 
per well, and each group had 3 wells. Cells were washed 
twice with phosphate-buffered saline (PBS) after incuba-
tion for 15 days at 37  °C, and then stained with Giemsa 
solution. The number of colonies containing  ≥50 cells 
was counted under a light microscope (Olympus, Orin-
pasu Kabushiki-gaisha, Japan).
Immunohistochemistry (IHC)
IHC was performed as previously described [17]. Sec-
tions of paraffin-embedded specimens (4  μm in thick-
ness) were baked and deparaffinized. Sections were 
stained with an anti-CEP78 antibody (Sigma Aldrich), 
and the antigen was detected using a secondary anti-
rabbit HRP-conjugated antibody. Subsequently, the sec-
tions were stained with 3,3′diaminobenzidine (DAB) and 
counterstained with hematoxylin. CEP78 expression was 
evaluated by two independent pathologists. The IHC 
staining score was calculated. Using the H-score method, 
we multiplied the percentage score by the staining inten-
sity score. The percentage of positively stained cells was 
scored as 0 (0%), 1 (1%–25%), 2 (26%–50  %), 3 (51%–
75%), or 4 (76%–100%). Staining intensity was scored as 0 
(negative staining), 1 (weak staining), 2 (moderate stain-
ing), or 3 (strong staining). The median score was chosen 
as the cut-off value to define low and high CEP78 expres-
sion [16].
Apoptosis assays
The effect of CEP78 on apoptosis was examined. HT29 
and HCT116 cells were transfected with a CEP78 over-
expression vector for 48 h. Cells were then collected by 
centrifugation at 1000 r/min for 10 min and treated with 
Annexin V-FITC and propidium iodide (Roche, New 
York, NY, USA) for 15  min. The cell suspension was 
immediately analyzed by flow cytometry (Beckman-
Coulter, Inc, Fullerton, CA, USA) to evaluate cell apopto-
sis. At least 10,000 events were collected for each sample.
Animal experiments
Twenty-four male BALB/c athymic nude mice (4  weeks 
old) were obtained from Guangdong Medical Laboratory 
Animal Center (Guangzhou, China). Mice were randomly 
separated into the empty vector group and the CEP78 
group with inoculation of HCT116 or HT29 cells. Each 
group included 6 mice. All animal experiments were per-
formed in the animal institute of SYSUCC according to 
the principles and procedures approved by the Medical 
Experimental Animal Care Commission of SYSUCC. To 
assess CRC tumor growth in  vivo, 1 ×  106 HCT116 or 
HT29 cells were injected subcutaneously into the dorsal 
Table 1 Association between  clinicopathologic variables 
of  colorectal cancer patients and  centrosomal protein 78 
(CEP78) expression





 ≤ 50 years 88 64 (72.7) 24 (27.3)
 > 50 years 149 102 (68.5) 47 (31.5)
Gender 0.102
 Female 110 82 (74.5) 28 (25.5)
 Male 127 84 (66.1) 43 (33.9)
Size 0.017
 ≤4 cm 68 40 (58.8) 28 (41.2)
 >4 cm 169 126 (74.6) 43 (25.4)
Differentiation 0.003
 Well 7 3 (42.9) 4 (57.1)
 Moderate 171 112 (65.5) 59 (34.5)
 Poor 59 51 (86.4) 8 (13.6)
Depth of tumor 0.060
 T1 + T2 44 26 (59.1) 18 (40.9)




 Absent 112 71 (63.4) 41 (36.6)




 Absent 178 118 (66.3) 60 (33.7)
 Present 59 48 (81.4) 11 (18.6)
Stage 0.011
 I + II 91 55 (60.4) 36 (39.6)
 III + IV 146 111 (76.0) 35 (24.0)
Page 4 of 9Zhang et al. Chin J Cancer  (2016) 35:62 
flank of each mouse. Tumor size was measured every 
2 days. After 20 days, the mice were euthanized, and the 
xenografts were weighed.
Statistical analysis
SPSS software (version 16.0, Chicago, IL, USA) was used 
for statistical analysis. The relationship between CEP78 
expression and the clinicopathologic parameters was exam-
ined by Student’s t test (Fisher’s exact test was chosen when 
the minimum expected cell count was less than 5). Over-
all survival (OS) curves were plotted by the Kaplan–Meier 
method and analyzed using the log-rank test. Univariate 
and multivariate Cox regression analyses were used to eval-
uate survival data. Differences were considered statistically 
significant when P values were less than 0.05 (two tailed).
Results
The expression level of CEP78 was decreased in CRC tissues
We detected the mRNA levels of CEP78 in CRC tissues 
and normal tissues by qRT-PCR. As shown in Fig.  1, 
CEP78 mRNA levels were significantly lower in most 
tumor tissues (5 out of 8) than in normal tissues.
To determine the potential relationship between 
CEP78 expression and CRC development, IHC analyses 
were performed to evaluate CEP78 protein levels in 237 
CRC samples. Overall, CEP78 was found to be mainly 
distributed in the cytoplasm of tumor and non-tumor 
cells (Fig.  2). According to the median score (5.85) of 
CEP78 staining, tissue samples were categorized into 
low and high CEP78 expression groups. Surprisingly, we 
found that high CEP78 expression was detected in 30.0% 
(71/237) of samples of tumor tissues and 89.2% (141/158) 
of samples of adjacent normal tissues (P < 0.001). These 
results indicated that CEP78 expression was significantly 
suppressed in tumor tissues during CRC development.
Association between CEP78 expression 
and clinicopathologic factors
Clinicopathologic factors were further analyzed between 
the high and low CEP78 expression groups. As shown 
in Table  1, CRC patients with low CEP78 expression 
had a higher tendency to exhibit poor differentiation 
(P  =  0.003), large tumor size (P  =  0.017), lymphatic 
metastasis (P  =  0.036), distant metastasis (P  =  0.019), 
and advanced stage (P = 0.008). However, we did not find 
significant associations between CEP78 expression and 
other clinicopathologic parameters, such as age, gender, 
and depth of tumor (P > 0.05).
Low expression of CEP78 was associated with poor 
prognosis in CRC patients
To test the prognostic value of CEP78 in CRC 
patients, Kaplan–Meier survival analyses were con-
ducted. In our cohort, 97 patients died of CRC. The 
median OS was 30.8  months. The 1-, 3-, and 5-year 
OS rates were 99.9%, 70.7%, and 60.2%, respectively. 
Of these 97 patients, 77 (79.4%) had low CEP78 
expression, whereas 20 (20.6%) had high CEP78 
expression. Kaplan–Meier survival analyses indicated 
that low CEP78 expression was associated with a poor 
prognosis (P =  0.008); poor prognosis was also asso-
ciated with large tumor size (P =  0.003), deep tumor 
invasion (P = 0.007), lymphatic metastasis (P < 0.001), 
distant metastasis (P  <  0.001), and advanced stage 
(P < 0.001) (Fig. 3).
Univariate analyses were also performed to examine 
the association between various factors and survival 
in our selected samples. The results shown in Table 2 
indicated a significant association between patient 
survival and CEP78 expression (P  =  0.009), tumor 
size (P  =  0.004), tumor depth (P  <  0.001), lymphatic 
metastasis (P  <  0.001), distant metastasis (P  <  0.001), 
and tumor stage (P  <  0.001). However, other clinico-
pathologic features, such as age, gender, and histo-
logic grade, were not significant prognostic factors 
(P  >  0.05). Moreover, multivariate analysis showed 
that tumor size, distant metastasis, and tumor stage 
(P < 0.05), but not CEP78 expression (P = 0.191), were 
independent prognostic indicators in patients with 
CRC (Table 2).
Fig. 1 The mRNA level of centrosomal protein 78 (CEP78) in 8 paired  
colorectal cancer (CRC) tissues and non-tumorous tissues. a CEP78 
mRNA levels in CRC tumor tissues (“T” on this panel) and the  
non-tumorous counterparts (“N” on this panel) were determined.  
b quantitative real-time polymerase chain reaction (qRT-PCR) was 
used to examine relative CEP78 mRNA expression. The normal/cancer 
ratio is shown
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Overexpression of CEP78 inhibited CRC proliferation 
in vitro
CEP78 was differently expressed in CRC cell lines 
(Fig. 4a). Two stable cell lines (HT29 and HCT116) over-
expressing CEP78 were established (Fig. 4b). MTT assay 
analysis indicated that cell viability was dramatically 
impaired in cells overexpressing CEP78 (Fig. 4c). Consist-
ently, the colony formation capability was also compro-
mised in CEP78-overexpressing cells compared with the 
control cells (Fig. 4d). Further study showed that overex-
pression of CEP78 resulted in G2/M arrest. For instance, 
the percentage of HCT116 cells at G2/M phase increased 
from 14.5% in control cells to 56.1% in CEP78-overex-
pressing cells (Fig. 4e). Annexin V/PI assays revealed that 
CEP78 had no effect on cell apoptosis (Fig. 4f ).
Overexpression of CEP78 impaired the growth of CRC 
in vivo
To further characterize the function of CEP78 in CRC 
development, tumor cells with or without CEP78 over-
expression were injected subcutaneously into nude mice, 
and both the weight and volume of tumors were meas-
ured 20 days after injection. The control groups showed 
rapid tumor growth. In sharp contrast, tumor growth 
was much slower in groups with CEP78 overexpression 
compared with the control groups, as indicated by the 
decreased weight and volume of tumors (Fig. 5a–c). The 
results of HE and IHC staining showed CEP78 overex-
pression in tumors formed by CRC cell lines (Fig. 5d).
Discussion
Centrosome amplification, a hallmark of cancer, accounts 
for the unlimited proliferation of human cancers. Cen-
trosome duplication is strictly controlled by a series of 
checkpoints in which CEPs play essential roles [6]. In this 
study, we showed that the expression of CEP78, a cen-
trosome component, was markedly decreased in a large 
cohort of 237 patients with CRC. The silencing of CEP78 
was closely associated with large tumor size, advanced 
tumor stage, lymphatic metastasis, and distant metasta-
sis. Because patients with CRC often experience metas-
tasis to the lymph nodes, liver, and lungs at late stages, 
CEP78 may serve as a predictor for tumor metastasis in 
CRC.
Patients with low CEP78 expression in our cohort were 
more likely to have shorter survival than those with high 
Fig. 2 Expression of CEP78 in CRC tissues is determined by immunohistochemistry (IHC). CEP78 is found in the cytoplasm of tumor cells and adja-
cent normal cells. a Representative image of CRC tissues with no expression of CEP78 and the adjacent normal tissues with strong expression.  
b Representative image of CRC tissues with weak expression of CEP78. c Representative image of CRC tissues with strong expression of CEP78
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CEP78 expression. It has been well known that centro-
some abnormality occurs in many types of cancer and 
is associated with poor outcomes [18]. Although no evi-
dence indicates that CEP78 plays a role in centrosome 
duplication, one of its homologous proteins, CEP76, has 
been demonstrated to regulate the centrosome redupli-
cation. Enforced CEP76 expression specifically inhibits 
centriole amplification but not normal centriole duplica-
tion [7], indicating that CEPs are capable of limiting cen-
trosome copies. Therefore, we assume that lack of CEP78 
results in centrosome amplification, and subsequently 
contributes to poor outcomes in CRC. Our data suggest 
that CEP78 may be of clinical significance, not only due 
to the large sample size in our study but also because 
CRC lacks common prognostic biomarkers.
CEPs are differentially expressed in human cancers. 
For example, CEP55 was demonstrated to be highly 
expressed in colon carcinoma [12], oral cavity squamous 
cell carcinoma [19], and bladder transitional cell carci-
noma [20]. Reduction in CEP63 expression was found 
in bladder cancer [21]. Our data revealed that CEP78 
expression was decreased in CRC. In vitro data showed 
that CEP78 overexpression significantly reduced cell via-
bility and colony formation of CRC HT29 and HCT116 
cells. The anti-tumor effect of CEP78 was further sup-
ported because CEP78 overexpression halted the growth 
of CRC xenografts. Mechanistically, CEP78 overexpres-
sion efficiently inhibited cell growth via arresting CRC 
Fig. 3 CEP78 expression is associated with overall survival of CRC 
patients. Patients with low CEP78 expression show a significantly 
poorer prognosis than those with high CEP78 expression. The asso-
ciations between poor prognosis and large tumor size, deep tumor 
invasion, lymphatic metastasis, distant metastasis, and advanced 
tumor stage were also examined. P value was calculated by the log-
rank test
Table 2 Univariate and  multivariate analyses of  prognostic values of  clinicopathologic features and  CEP78 expression 
for overall survival of CRC patients
HR hazard ratio, CI confidence interval
Variable Univariate analysis Multivariate analysis
HR (95 % CI) P value HR (95 % CI) P value
Age (≤50 years vs. >50 years) 0.994 (0.658–1.501) 0.976
Gender (female vs. male) 1.072 (0.719–1.597) 0.733
Tumor size (≤4 cm vs. >4 cm) 2.125 (1.273–3.548) 0.004 1.873 (1.095–3.323) 0.022
Tumor differentiation (well vs. moderate vs. poor) 0.214 (0.029–1.574) 0.096
Depth of tumor (T1 + T2 vs. T3 + T4) 4.881 (2.129–11.19) <0.001 0.815 (0.450–1.477) 0.500
Lymphatic metastasis (absent vs. present) 3.714 (2.351–5.865) <0.001 1.537 (0.830–2.847) 0.172
Distant metastasis (absent vs. present) 4.954 (3.283–7.475) <0.001 2.744 (1.701–4.425) <0.001
TNM stage (I + II vs. III + IV) 7.373 (4.003–13.58) <0.001 3.642 (1.492–8.894) 0.005
CEP78 expression (low vs. high) 0.520 (0.318–0.852) 0.009 0.787 (0.475–1.305) 0.354
(See figure on next page.) 
Fig. 4 Overexpression of CEP78 in CRC cells inhibits cell viability in vitro. a Expression of CEP78 in CRC cell lines was determined by western blot-
ting. b CEP78 protein levels were examined by western blotting in cells with or without CEP78 overexpression. c MTT assay results showed a sig-
nificant reduction of viability in cells with CEP78 overexpression. d Colony formation was decreased in cells with CEP78 overexpression. The results 
of colony assay quantification are indicated as the mean ± standard error of the mean (SEM) of three independent experiments. *P < 0.05. e Cells 
were transfected with CEP78 or empty vector for 48 h. The distributions of cell cycle were determined by flow cytometry analyses. f Cells treated as 
described in e were subjected to apoptosis analyses, using Annexin V/PI staining
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cells at the G2/M phase. This is consistent with the roles 
of other CEPs in cell cycle regulation. Slaats et  al. [22] 
showed that knockdown of CEP164 expression led to S 
phase arrest in renal cells. Ruiz-Miró et al. [23] reported 
that overexpression of CEP57 hindered NIH-3T3 cells at 
S phase. In our study, cell apoptosis was not observed in 
Fig. 5 Overexpression of CEP78 in CRC cells impairs tumor growth in vivo. a Tumors were excised 20 days after injection. b The average weight 
of tumors from indicated cells in each group was assessed. c The average volume of tumors from indicated cells was measured every 2 days after 
injection. *P < 0.05. d The xenografts were sectioned and stained by hematoxylin and eosin (HE) or immunohistochemistry (IHC) with CEP78 anti-
body
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CRC cells with CEP78 overexpression. Collectively, our 
data provide evidence that CEP78 controls cell prolifera-
tion partly by modulating G2/M phase transition.
In summary, our data show that the expression of 
CEP78 is remarkably decreased in patients with CRC. 
Furthermore, the expression of CEP78 is robustly related 
to unfavorable clinical outcomes in patients with CRC. 
CEP78 overexpression suppressed cell growth via induc-
ing G2/M phase arrest. This study therefore suggests 
CEP78 as a potential prognostic and therapeutic bio-
marker for CRC.
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